Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

γ-Glutamylamines and neurodegenerative diseases.

Jeitner TM, Battaile K, Cooper AJ.

Amino Acids. 2013 Jan;44(1):129-42. doi: 10.1007/s00726-011-1209-3. Epub 2012 Mar 10. Review.

2.
3.
4.

Probing the specificity of gamma-glutamylamine cyclotransferase: an enzyme involved in the metabolism of transglutaminase-catalyzed protein crosslinks.

Bowser TE, Trawick ML.

Amino Acids. 2013 Jan;44(1):143-50. doi: 10.1007/s00726-011-1153-2. Epub 2011 Nov 27.

PMID:
22120669
5.

Increased levels of gamma-glutamylamines in Huntington disease CSF.

Jeitner TM, Matson WR, Folk JE, Blass JP, Cooper AJ.

J Neurochem. 2008 Jul;106(1):37-44. doi: 10.1111/j.1471-4159.2008.05350.x. Epub 2008 Jul 1.

6.

Spectrophotometric assays for L-lysine alpha-oxidase and gamma-glutamylamine cyclotransferase.

Danson JW, Trawick ML, Cooper AJ.

Anal Biochem. 2002 Apr 15;303(2):120-30.

PMID:
11950211
7.

Identification and characterization of gamma-glutamylamine cyclotransferase, an enzyme responsible for gamma-glutamyl-epsilon-lysine catabolism.

Oakley AJ, Coggan M, Board PG.

J Biol Chem. 2010 Mar 26;285(13):9642-8. doi: 10.1074/jbc.M109.082099. Epub 2010 Jan 28.

8.

Possible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseases.

Martin A, Giuliano A, Collaro D, De Vivo G, Sedia C, Serretiello E, Gentile V.

Amino Acids. 2013 Jan;44(1):111-8. doi: 10.1007/s00726-011-1081-1. Epub 2011 Sep 22. Review.

PMID:
21938398
9.
10.
11.

[Protein modification by transglutaminase].

Hitomi K.

Seikagaku. 2005 Jun;77(6):552-8. Review. Japanese. No abstract available.

PMID:
16022432
12.

In situ enzymatic activity of transglutaminase isoforms on brain tissue sections of rodents: A new approach to monitor differences in post-translational protein modifications during neurodegeneration.

Schulze-Krebs A, Canneva F, Schnepf R, Dobner J, Dieterich W, von Hörsten S.

Brain Res. 2016 Jan 15;1631:22-33. doi: 10.1016/j.brainres.2015.11.027. Epub 2015 Nov 23.

PMID:
26616340
13.

Post-translational modification of glutamine and lysine residues of HIV-1 aspartyl protease by transglutaminase increases its catalytic activity.

Lentini A, Tabolacci C, Melino S, Provenzano B, Beninati S.

Biochem Biophys Res Commun. 2010 Mar 12;393(3):546-50. doi: 10.1016/j.bbrc.2010.02.060. Epub 2010 Feb 17.

PMID:
20170637
14.

Presence of di- and polyamines covalently bound to protein in rat liver.

Beninati S, Piacentini M, Argento-Cerù MP, Russo-Caia S, Autuori F.

Biochim Biophys Acta. 1985 Jul 26;841(1):120-6.

PMID:
2861856
15.

Transglutaminases and neurodegeneration.

Jeitner TM, Pinto JT, Krasnikov BF, Horswill M, Cooper AJ.

J Neurochem. 2009 May;109 Suppl 1:160-6. doi: 10.1111/j.1471-4159.2009.05843.x. Review.

16.
17.

Transglutaminases - possible drug targets in human diseases.

Gentile V, Cooper AJ.

Curr Drug Targets CNS Neurol Disord. 2004 Apr;3(2):99-104. Review.

PMID:
15078184
18.

Transglutaminase-catalyzed crosslinking in neurological disease: from experimental evidence to therapeutic inhibition.

Hoffner G, André W, Vanhoutteghem A, Souès S, Djian P.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):217-31. Review.

PMID:
19811443
19.

gamma-Glutamylamine derivatives in isolated rat hepatocyte proteins.

Piacentini M, Beninati S.

Biochem J. 1988 Feb 1;249(3):813-7.

20.

Transglutaminase is linked to neurodegenerative diseases.

Muma NA.

J Neuropathol Exp Neurol. 2007 Apr;66(4):258-63. Review.

PMID:
17413316

Supplemental Content

Support Center